You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲南白藥(000538.SZ):徵武科技的JZ-14膠囊獲得藥物臨牀試驗批準

格隆匯6月17日丨雲南白藥(000538.SZ)公佈,公司控股子公司雲白藥徵武科技(上海)有限公司(簡稱“徵武科技”)於近日收到國家藥品監督管理局下發的《藥物臨牀試驗批準通知書》(通知書編號:2025LP01506、2025LP01507)。經審查,徵武科技的JZ-14膠囊(以下簡稱“本品”)臨牀試驗申請符合藥品註冊的有關要求,同意本品開展潰瘍性結腸炎的臨牀試驗。

本品爲徵武科技自主研發的化學1類創新藥,是First-in-Class(首創新藥)的小分子免疫調節劑。JZ-14可選擇性結合特定的蛋白靶點,抑制其下遊AKT/NF-κB等信號通路,從而在潰瘍性結腸炎與多種腫瘤模型中展現出顯著的免疫調節及抗增殖活性。截至目前,針對本品已投入研發費用約人民幣2,600萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account